Coralan (Ivabradine)
ivabradine 5 mg tablet, 56 · ORAL · PBS code 15270Q
STREAMLINEDWhat it costs
AU$31.03 PBS-determined price per 112 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2026-03-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Chronic heart failure
The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
Patient must be symptomatic with NYHA classes II or III; AND
Patient must be in sinus rhythm; AND
Patient must have a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%; AND
Patient must have a resting heart rate at or above 77 bpm at the time ivabradine treatment is initiated; AND
Patient must receive concomitant optimal standard chronic heart failure treatment, which must include the maximum tolerated dose of a beta-blocker, unless contraindicated or not tolerated.
Resting heart rate should be measured by ECG or echocardiography, after 5 minutes rest.
The ECG or echocardiography, result must be documented in the patient's medical records when treatment is initiated.
Sponsor: Servier Laboratories (Aust.) Pty. Ltd. ABN 54 004 838 500
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.